Canonical (Smads) and non-canonical (via TGFβRI-ICD or ALK5-ICD) TGF-β signaling was significantly positively associated with tumor progression and poor patient survival in ccRCC [65]. This evidence concerns the gene TGFB1 and nonpapillary renal cell carcinoma.